Irrespective of these unknowns, our evidence is relevant therapeutically as MRE11i + RAD51i depletes CRC-SCs without the concurrent presence of endogenous/exogenous RS sources or exposure to ATR/CHK1 inhibitors. Here, CHEK1 is linked to colorectal carcinoma.